Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to take part and to allow their personal health information to be shared as part of the study.
- People who are 18 years of age or older at the time of giving consent.
- People who have a relatively good level of physical functioning, rated 0 or 1 on a standard scale used in cancer research (confirm with trial site for details on what this means in practice).
- People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed through a tissue or cell sample.
- Women who could become pregnant must be willing to either avoid heterosexual activity or use two reliable forms of contraception from the time of consent until 6 months after finishing the study treatment.
- Men with female partners must either have had a vasectomy or agree to use a double barrier method of contraception (such as a condom plus spermicidal agent) from the first dose of treatment through 3 months after the cell infusion therapy.
Who may not be able to join:
- People who have or have had another type of cancer whose history or treatment could affect how safely or accurately the study results can be assessed.
- People who, in the judgment of the study doctor, are not willing or able to follow the study procedures as required.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ashwin Somasundaram, MD, UNC Lineberger Comprehensive Cancer Center
Phone: +1 919-445-4208
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse event; Cytokine Release Syndrome; Neurotoxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.